'Intermittent' versus 'continuous' ScvO<sub>2</sub> monitoring in children with septic shock: a randomised, non-inferiority trial.

Sankar, Jhuma; Singh, Man; Kumar, Kiran; Sankar, M Jeeva; Kabra, Sushil Kumar; Lodha, Rakesh · Intensive Care Med · 2020

rct · Level II

Where this comes from

Abstract

To compare the effect of 'intermittent' central venous oxygen saturation (ScvO<sub>2</sub>) monitoring with 'continuous' ScvO<sub>2</sub> monitoring on shock resolution and mortality in children with septic shock. Primary outcome was the achievement of therapeutic goals or shock resolution in the first 6 h. We randomly assigned children < 17 years' age with septic shock to 'intermittent ScvO<sub>2</sub>' or 'continuous ScvO<sub>2</sub>' groups. All children were subjected to subclavian/internal jugular line insertion and managed as per Surviving Sepsis Campaign Guidelines. To guide resuscitation, we used ScvO<sub>2</sub> estimated at other clinical and laboratory parameters were monitored similarly in both groups. We enrolled 75 and 77 children [median (IQR) age: 6 (1.5-10) years] in the 'intermittent' and 'continuous' groups, respectively. Baseline characteristics were comparable between the groups. When compared to the 'continuous' group, fewer children in the 'intermittent' group achieved shock resolution within first 6 h [19% vs. 36%; relative risk (RR) 0.51; 95% CI 0.29-0.89; risk difference - 18.0%; 95% CI - 32.0 to - 4.0]. The lower bound of confidence interval, however, crossed the pre-specified non-inferiority margin. There was no difference in the proportion of children attaining shock resolution within 24 h (63% vs. 69%; RR 0.86; 95% CI 0.68-1.08) or risk of mortality between the groups (47% vs. 43%; RR 1.06; 95% CI 0.74-1.51). Given that a greater proportion of children attained therapeutic end points in the first 6 h, continuous monitoring of ScvO<sub>2</sub> should preferably be used to titrate therapy in the first few hours in children with septic shock. In the absence of such facility, intermittent monitoring of ScvO<sub>2</sub> can be used to titrate therapy in these children, given the lack of difference in the proportion of patients achieving shock resolution at 24 h or in risk of mortality between the intermittent and continuous groups.

Medical subject headings